QUTENZA
Drug
Averitas Pharma Inc.
Total Payments
$5.7M
Transactions
29,219
Doctors
12,617
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.4M | 14,977 | 7,531 |
| 2023 | $2.3M | 14,240 | 7,330 |
| 2017 | $30.94 | 2 | 2 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.9M | 1,136 | 51.4% |
| Honoraria | $1.2M | 574 | 20.3% |
| Food and Beverage | $817,997 | 25,916 | 14.3% |
| Travel and Lodging | $360,802 | 1,366 | 6.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $249,578 | 154 | 4.4% |
| Consulting Fee | $141,019 | 50 | 2.5% |
| Royalty or License | $33,817 | 3 | 0.6% |
| Grant | $15,469 | 1 | 0.3% |
| Education | $729.55 | 19 | 0.0% |
Payments by Type
Research
$2.9M
1,136 transactions
General
$2.8M
28,083 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | Averitas Pharma Inc. | $2.9M | 0 |
Top Doctors Receiving Payments for QUTENZA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Mel Colon | — | Atlanta, GA | $2.9M | 1,142 |
| , MD | Interventional Pain Medicine | Pikesville, MD | $155,798 | 235 |
| , DPM | Podiatrist | Nashville, TN | $153,333 | 199 |
| , DPM | Foot & Ankle Surgery | Allentown, PA | $142,799 | 193 |
| , APRN | Nurse Practitioner | Topeka, KS | $132,056 | 296 |
| Alaa Abd-Elsayed | Pain Medicine | Madison, WI | $131,669 | 135 |
| , D.O | Pain Medicine | Germantown, MD | $129,096 | 191 |
| , M.D | Neurology | Dallas, TX | $110,448 | 206 |
| , MD | Pain Medicine | Winston Salem, NC | $97,957 | 161 |
| , M.D | Pain Medicine | New Orleans, LA | $82,644 | 106 |
| , ARNP | Family | Kansas City, KS | $79,860 | 164 |
| , MD | Internal Medicine | Morristown, NJ | $75,162 | 17 |
| , MD | Pain Medicine | Greensburg, PA | $72,074 | 78 |
| , M.D | Neurology | San Diego, CA | $63,033 | 150 |
| , MD | Pain Medicine | Los Angeles, CA | $61,146 | 51 |
| , M.D, M.P.H | Neurology | Denver, CO | $49,012 | 124 |
| , APRN | Family | Omaha, NE | $37,898 | 83 |
| , DO | Physical Medicine & Rehabilitation | Seattle, WA | $34,731 | 44 |
| , D.P.M | Podiatrist | Gladstone, MO | $31,986 | 27 |
| , N.P | Nurse Practitioner | Stanford, CA | $27,566 | 36 |
| , MD, FACE | Endocrinology, Diabetes & Metabolism | Gulfport, MS | $27,088 | 62 |
| , M.D | Interventional Pain Medicine | San Francisco, CA | $24,793 | 44 |
| , MD | Pain Medicine | The Woodlands, TX | $23,268 | 44 |
| , MD | Neurology | New York, NY | $21,318 | 2 |
| , MD MPH | Interventional Pain Medicine | Rochester, NY | $20,320 | 26 |
Ad
Manufacturing Companies
- Averitas Pharma Inc. $5.7M
- GRT US Holding, Inc. $664.61
- Acorda Therapeutics, Inc $30.94
Product Information
- Type Drug
- Total Payments $5.7M
- Total Doctors 12,617
- Transactions 29,219
About QUTENZA
QUTENZA is a drug associated with $5.7M in payments to 12,617 healthcare providers, recorded across 29,219 transactions in the CMS Open Payments database. The primary manufacturer is Averitas Pharma Inc..
Payment data is available from 2017 to 2024. In 2024, $3.4M was paid across 14,977 transactions to 7,531 doctors.
The most common payment nature for QUTENZA is "Unspecified" ($2.9M, 51.4% of total).
QUTENZA is associated with 1 research study, including "AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN" ($2.9M).